Results 51 to 60 of about 848 (155)
Antimicrobial Agents and Chemotherapy, 2023 Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or ...
Jose A. Vazquez +9 more
openaire +3 more sources
Fungal Cell Wall: Emerging Antifungals and Drug Resistance
Frontiers in Microbiology, 2019 The cell wall is an essential component in fungal homeostasis. The lack of a covering wall in human cells makes this component an attractive target for antifungal development. The host environment and antifungal stress can lead to cell wall modifications
Soraia L. Lima +2 more
doaj +1 more source
TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression [PDF]
Candida auris is an emerging pathogenic fungus that is highly resistant to existing antifungal drugs. Manogepix is a novel antifungal agent that exerts antifungal activity by inhibiting glycosylphosphatidylinositol anchor biosynthesis.
34876 +17 more
core +4 more sources
Antifungal metabolites, their novel sources, and targets to combat drug resistance [PDF]
, 2022 Excessive antibiotic prescriptions as well as their misuse in agriculture are the main causes of antimicrobial resistance which poses a growing threat to public health. It necessitates the search for novel chemicals to combat drug resistance.
Choudhary, Megha +6 more
core +1 more source
Exploring the Depths of Cryptic Aspergillosis: Species Variability, Clinical Spectrum, Diagnostic Quandaries and Therapeutic Options [PDF]
Journal of Clinical and Diagnostic ResearchCryptic aspergillosis, characterised by infections caused by non classical Aspergillus species, presents unique challenges in clinical management due to species variability, diverse clinical manifestations, diagnostic complexities, and limited treatment ...
Almas Fathima Upaisal +1 more
doaj +1 more source
Navigating the rise of Fusarium meningitis: perspective on the insights and therapeutic approaches. [PDF]
EXCLI JFaheem MSB, Farooq O.
europepmc +3 more sources
Hope on the horizon: Novel fungal treatments in development [PDF]
, 2020 The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance.
Coler-Reilly, Ariella +3 more
core +1 more source
Antagonism of the Azoles to Olorofim and Cross-Resistance Are Governed by Linked Transcriptional Networks in Aspergillus fumigatus [PDF]
, 2022 Aspergillosis, in its various manifestations, is a major cause of morbidity and mortality. Very few classes of antifungal drugs have been approved for clinical use to treat these diseases and resistance to the first-line therapeutic class, the triazoles ...
Amich, Jorge +8 more
core +3 more sources
Open Forum Infectious Diseases, 2023 Abstract Background Candida auris (CAU) epidemiology is evolving rapidly. Manogepix is the active moiety of the novel prodrug antifungal fosmanogepix (FMGX), and has broad-spectrum activity against yeasts and moulds, including CAU.
Carvalhaes, Cecilia G +4 more
openaire +1 more source
Epidemiology of Invasive Candidiasis. [PDF]
Invasive candidiasis (IC) is an increasingly prevalent, costly, and potentially fatal infection brought on by the opportunistic yeast, Candida. Previously, IC has predominantly been caused by C. albicans which is often drug susceptible.
Bays, Derek +8 more
core +4 more sources